問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Surgery

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

National Cheng Kung University Hospital Dou-Liou Branch (在職)

Division of General Internal Medicine

更新時間：2023-09-19

蔡瑞鴻Tsai, Jui-Hung
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 10 個月

Recruiting Trial

168Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡瑞鴻

List

230Cases

2017-10-11 - 2022-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2018-12-07 - 2024-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-11-01 - 2021-12-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2023-03-11 - 2027-03-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2019-06-01 - 2025-12-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-09-15 - 2026-10-01

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-03-09 - 2026-12-15

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2022-05-10 - 2026-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2022-11-30 - 2027-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2022-02-28 - 2026-12-10

Phase I/II

Active
An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation

  • Condition/Disease

    Advanced Non-small Cell Lung Cancer、EGFR Mutation、HER2 Mutation

  • Test Drug

    BAY 2927088

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting2Sites

Terminated3Sites

1 16 17 18 19 20 23
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB